MedX Health Corp. announced that the company will be expanding its sales and marketing efforts with the new European master distributor MMB GmbH. Earlier in 2009 MedX Health had announced the establishment of its first European Distribution Center in the Netherlands. The new partner company MMB (Medical Marketing Berlin GmbH) is located in the capital of the biggest European health care market (Germany) and focused on marketing and sales of the MedX Health Laser therapy products. The MMB GmbH is focused on serving the sales and marketing needs of North American health care companies and their market entry to Europe.

MedX Health Corp. reported its earnings results for the second quarter and six months ended June 30, 2009. Revenue for the quarter was $106,624, a 58.9% decrease over the same period in 2008 where revenue was $259,235. The company incurred a loss from continuing operations for the quarter of $538,971 or $0.02 per basic and diluted share compared to a loss of $823,190 or $0.04 per basic and diluted share for the same period in the prior year. Loss for the period was $538,971 against $817,465 for same period a year ago. Revenues for the 6 month period ending June 30, 2009 was $458,200, a 17.4% decline from the 6 month period in the prior year. The loss for the 6 month period was $1,007,334 in 2009 compared to loss for the 6 month period last year of $1,510,334.

MedX Health Corp. announced that, subject to TSX Venture Exchange approval, it plans to form a limited partnership, MedX Health Finance Partnership. The general partner of MedX LP will be a wholly-owned subsidiary of MedX Corp. incorporated for this purpose. The term of MedX LP is expected to end on December 31, 2019. MedX Corp. is expected to make an offer in 2013 to acquire all the MedX LP units outstanding at that time at fair market value, as determined by an independent firm of Canadian chartered accountants, in exchange for common shares of MedX Corp. at a price based on the average trading price of MedX Corp.'s common shares over 20 trading days. Pursuant to the terms of a royalty agreement to be entered into between MedX LP and MedX Corp., MedX LP will market all of MedX Corp's. light-related products. MedX LP will receive 100% of the revenue from all global sales of these products and will pay MedX Corp. a 10% royalty fee on gross sales of the products. Pursuant to the terms of the management services agreement to be entered into between MedX LP and MedX Corp., MedX LP will use these revenues to pay MedX Corp. all of its costs associated with the manufacturing and sale of the products plus an annual incentive fee. The annual incentive fee shall be calculated based on 15% of sales until net income is achieved, and after net income is achieved it will be based on a percentage of net income ranging from a low of 0% for net income below $1 Million to a high of 80% for net income exceeding $8 Million. MedX Corp. will provide MedX LP with management, administrative, and marketing services, plus customer lists under the terms of the management services agreement.